| Family: | ProShares |
| Name: | ProShares Ultra Nasdaq Biotechnology |
| Inception Date: | 7-Apr-2010 |
| Termination Date: | |
| Investment Objective: | ProShares Ultra Nasdaq Biotechnology seeks daily investment results before fees and expenses that correspond to twice (200%) the daily performance of the NASDAQ Biotechnology Index. |
| Prospectus | |
| Top 10 Holdings | ||
| Derivatives offset | -130.1836% | |
| NASDAQ Bio Index SWAP BNP Paribas | 39.2341% | |
| Net Other Assets (Liabilities) | 30.4605% | |
| NASDAQ Biotechnology Index SWAP Citibank NA | 29.2797% | |
| NASDAQ Biotechnology Index SWAP Bank of America NA | 23.4967% | |
| NASDAQ Biotechnology Index SWAP Goldman Sachs International | 17.5015% | |
| NASDAQ Biotechnology Index SWAP Societe Generale | 16.4736% | |
| GILEAD SCIENCES INC | GILD | 6.3345% |
| VERTEX PHARMACEUTICALS INC | VRTX | 6.2664% |
| AMGEN INC | AMGN | 5.6704% |
| Top 10 Holdings Weight: | 44.5% |
| Number of Holdings: | 272 |
| Shares Outstanding: | 1,050,000 |
| Total Net Assets: | 89,139,430 |
| NAV: | 84.90 |
| Net Expense Ratio: | 0.95% |
| Asset Class: | Equities (Stocks) |
| Developed or Emerging: | Developed Market Funds |
| Country: | US |
| Region: | |
| Strategy: | |
| Currency: | |
| Commodity: | |
| Sector: | Healthcare |
| Industry: | Biotech |
| Dividend Type: | |
| Tax Exempt State: | |
| Maturity Duration: | |
| Market Cap: | Broad Market / Multi-Cap |
| Credit Quality: | |
| Mortgage Bond Types: | |
| Bond Type: | |
| Gov't Bond Types: | |
| Reit Type: | |
| Leverage Direction/Factor: | Leveraged (2x) |
| Is Currency Hedged: | No |
| US or Ex-US: | Domestic |
